An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. Pascal Touchon, President and CEO, to discuss the company's T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases. Webcast available on atarabio.com.
Positive
None.
Negative
None.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:00 p.m. PDT / 4:00 p.m. EDT.
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on Twitter and LinkedIn.
What is Atara Biotherapeutics, Inc. (Nasdaq: ATRA) presenting at the Canaccord Genuity 43rd Annual Growth Conference?
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) will present its T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases at the Canaccord Genuity 43rd Annual Growth Conference.
Who will be speaking at the conference?
Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics, Inc. (Nasdaq: ATRA), will be speaking at the conference.
Where can I watch the presentation?
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com.
How long will the webcast be available for replay?
An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
